Acalabrutinib + Bendamustine + Rituximab + Placebo
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, Mantle Cell
Conditions
Lymphoma, Mantle Cell
Trial Timeline
Apr 5, 2017 → Feb 15, 2027
NCT ID
NCT02972840About Acalabrutinib + Bendamustine + Rituximab + Placebo
Acalabrutinib + Bendamustine + Rituximab + Placebo is a phase 3 stage product being developed by AstraZeneca for Lymphoma, Mantle Cell. The current trial status is active. This product is registered under clinical trial identifier NCT02972840. Target conditions include Lymphoma, Mantle Cell.
What happened to similar drugs?
18 of 20 similar drugs in Lymphoma, Mantle Cell were approved
Approved (18) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02972840 | Phase 3 | Active |
Competing Products
20 competing products in Lymphoma, Mantle Cell